Allogenetics Raises €3.8M Seed to Advance One-Time Gene Therapy for Donor Organs

Allogenetics Closes €3.8M Seed Round

Hanover-based biotechnology company Allogenetics has raised €3.8 million in seed funding to advance its organ-agnostic gene therapy platform. The round was led by NBank Capital, with participation from Carma Fund and Life Science Valley Growth Fund.

What Allogenetics Does

Allogenetics is developing a one-time ex vivo gene therapy that modifies donor organs so the recipient's immune system no longer recognizes them as foreign. The approach is designed to reduce or eliminate the need for immunosuppressants after transplantation.

The company's lead program, ALG-115, calibrates MHC class I and II antigen presentation on the graft. In a pig model of lung transplantation, the program has shown eight-year survival without immunosuppressants. Allogenetics is advancing the platform toward first-in-human trials in lung transplantation, with kidney, heart, and liver programs in earlier stages.

Funding Details

• Round type: Seed
• Amount raised: €3,800,000
• Currency: EUR
• Date: September 9, 2026
• Lead investor: NBank Capital
• Investors: Carma Fund, NBank Capital, Life Science Valley Growth Fund

Why This Matters for the Market

Organ transplantation currently depends on lifelong immunosuppression, which carries significant side effects and long-term health risks. Allogenetics' ex vivo approach aims to modify the donor organ itself before transplantation, potentially making the graft invisible to the recipient's immune system. If successful in human trials, this could represent a fundamental shift in transplant medicine.

The preclinical data—eight-year survival without immunosuppressants in a pig lung transplant model—provides a strong proof of concept. The organ-agnostic nature of the platform means the same underlying technology could be applied across multiple organ types, expanding the potential patient population and commercial opportunity.

Acquisition Angle

For pharmaceutical and biotechnology companies with interests in gene therapy, immunology, or transplantation, Allogenetics offers a differentiated platform with early but compelling preclinical validation. The seed funding will support the company's progression toward first-in-human trials in lung transplantation, a critical value inflection point. Strategic acquirers may see potential in the platform's applicability beyond lung to kidney, heart, and liver programs.

What to Watch

• Progress toward first-in-human trials for ALG-115 in lung transplantation.
• Advancement of earlier-stage kidney, heart, and liver programs.
• Additional preclinical or clinical data validating the platform's durability and safety.
• Follow-on financing or partnership interest from larger transplant-focused organizations.

As Allogenetics moves from preclinical work into human testing, the company's ability to translate its pig-model results into clinical benefit will be central to its next phase of growth and to any future acquisition or licensing discussions.